KIMS partners with UAIMS Hospital
This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years
This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years
Theatre (OTs) dedicated to cataract, LASIK, and retina treatments added to meet the growing demand
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
Offers affordable, high-quality solutions for diabetes care
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Next-generation lens features purely refractive design, delivering uninterrupted high-quality vision with high best-in-category contrast & low-light performance
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
Subscribe To Our Newsletter & Stay Updated